Amneal製藥 AMRX 深 滬
交易中 06-24 11:29:24 美东时间
17.08
+0.420
+2.52%
華盛通- 最 高17.3699
- 今 開16.81
- 成交量 60.04万股
- 最 低 16.81
- 昨 收 16.66
- 總市值 54.49亿
- 52周最高 17.3699
- 市盈率 靜 77.01
- 換手率 0.19%
- 52周最低 7.665
- 委 比 33.33%
- 總股本 3.19亿
- 歷史最高 24.48
- 量 比 1.14
- 振 幅 3.36%
- 歷史最低 1.24
- 每 手 1
- 風險率 2.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FOCUS-US progesterone supplies tighten as menopause treatment demand grows
FOCUS-US progesterone supplies tighten as menopause treatment demand grows By Mrinalika Roy and Sriparna Roy June 17 (Reuters) - U.S. supplies of progesterone are coming under strain, with patients, clinicians, and pharmacists reporting recent intermittent shortages of oral versions of the hormone u
06-17 18:00
Top 3 Health Care Stocks That May Collapse This Quarter
As of June 15, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices ...
06-15 20:51
Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
Amneal's Commitment Helps Support a Reliable Supply of Essential Medicines for Uninsured and Underserved Patients Nationwide NASHVILLE, Tenn., June 10, 2026 /PRNewswire/ -- Dispensary of Hop...
06-10 22:09
Amneal Pharmaceuticals Announces New Interim Results From Phase 4 Study Reinforcing Reported Benefits Of Parkinson's Treatment Crexont
Overall Interim Findings (Entire Study Population, 214Patients; Six-Week Analysis)All 214 patients who switched to CREXONT (mean age 67.1±9.07 years):Increased Daily "Good On" Time:+3.33 hours when switching from IR
06-05 20:02
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
Amneal Pharmaceuticals announced positive interim results from its Phase 4 ELEVATE-PD study, showing that CREXONT (carbidopa and levodopa) extended-release capsules provide clinically meaningful benefits for Parkinson’s disease patients. The study of 214 patients demonstrated significant increases in daily “Good On” time, reductions in “Off” time, and improved motor function across all prior treatment groups. Patients switching from RYTARY experi...
06-05 12:00
Amneal Pharmaceuticals Romidepsin Injection Solution Receives FDA Approval
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's romidepsin injection solution, 27.5 mg/5.5 mL, supplied
06-04 20:05
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
Amneal Pharmaceuticals received FDA approval for its ready-to-use romidepsin injection solution, offering a convenient alternative to lyophilized powder. As a Competitive Generic Therapy, it secures 180 days of market exclusivity and strengthens Amneal's injectables portfolio. The product eliminates reconstitution steps, improving safety and efficiency for healthcare providers. Romidepsin is indicated for cutaneous T-cell lymphoma and has common ...
06-04 12:00
美股大行评级 | Cava、CrowdStrike、Keysight获多家大行上调目标价；家得宝绩后遭多家大行下调目标价
今日重点评级关注：Oppenheimer：维持Protara Therapeutics"跑赢大市"评级，目标价从25美元升至28美元；Piper Sandler：维持Bright Minds Biosciences"超配"评级，目标价从190美元升至220美元
05-21 12:05
Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $16
Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $15 to $16.
05-20 21:50
Amneal Pharmaceuticals beats top-line and bottom-line estimates; reaffirms FY26 outlook
Amneal Pharmaceuticals press release (AMRX): Q1 Non-GAAP EPS of $0.27 beats by $0.10. Revenue of $722.52M (+3.9% Y/Y) beats by $5.74M. Adjusted EBITDA in the first quarter of 2026 was $202 million, an...
05-08 12:51
